**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).


**Copyright:** © 2021 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorial**

**1367** What is the optimal target for a T2T approach in axial spondyloarthritis?

 OPEN ACCESS  
*J Sieper, D Poddubnyy*

**Heroes and pillars of rheumatology**

**1370** Clemens von Pirquet

*C Scheinecker, D Kraft*

**Viewpoint**

**1373** Ultrasound definition of enthesitis in spondyloarthritis and psoriatic arthritis: arrival or starting point?


*E Filippucci, G Smerilli, A Di Matteo, W Grassi*

**Rheumatoid arthritis**

**1376** Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial

*S Jain, V Dhir, A Aggarwal, R Gupta, B Leishangthem, S Naidu, A Khullar, S Maurya, V Dhawan, S K Sharma, A Sharma, S Jain*

**1385** Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis

 EDITOR'S CHOICE  
*T M Johnson, H R Sayles, J F Baker, M D George, P Roul, C Zheng, B Sauer, K P Liao, D R Anderson, T R Mikuls, B R England*

**1393** Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease

*M-H Chen, I-C Lee, M-H Chen, M-C Hou, C-Y Tsai, Y-H Huang*

**1400** Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

*H Nabi, S Georgiadis, A G Loft, O Hendricks, D V Jensen, M Andersen, S Chrysidis, A Colic, K Danebod, M R Hussein, M H Kalisz, S Kristensen, N Lomborg, N Manilo, H L Munk, J K Pedersen, J L Raun, F Mehnert, N S Krogh, M L Heiland, B Glinborg*

**Psoriatic arthritis**

**1410** Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis.

 OPEN ACCESS  
Data from the EuroSpA collaboration  
*U Lindström, D Di Giuseppe, B Delcoigne, B Glinborg, B Möller, A Ciurea, M Pombo-Suarez, C Sanchez-Piedra, K Eklund, H Relas, B Gudbjornsson, T J Love, G T Jones, C Codreanu, R Ionescu, L Nekevindova, J Závada, N Atas, S Yolbas, K M Fagerli, B Michelsen, Ž Rotar, M Tomšič, F Iamone, M J Santos, P Avila-Ribeiro, L M Ornbjerg, M Østergaard, L TH Jacobsson, J Asklings, M J Nissen*

**1419** Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results

 OPEN ACCESS  
*J S Smolen, S Siebert, T V Korotaeva, C Selmi, P Bergmans, E Gremese, B Joven-Ibáñez, G Katsifis, W Noël, M T Nurmohamed, P Richette, P P Sfikakis, K de Vlam, E Theander, L Gossec*

**1429** Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis

*K Colaco, K-A Lee, S Akhbari, R Winer, P Welsh, N Sattar, I B McInnes, V Chandran, P Harvey, R J Cook, D D Gladman, V Piquet, L Eder*

**Spondyloarthritis**

**1436** Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial

 OPEN ACCESS  
*A Molto, C López-Medina, F E Van den Bosch, A Boonen, C Webers, E Dernis, F A van Gaalen, M Soubrier, P Claudepierre, A Baillet, M Starmans-Kool, A Spoorenberg, P Jacques, P Carron, R Joos, J Lenaerts, L Gossec, S Pouplin, A Ruyssen-Witrand, L Sparsa, A van Tubergen, D van der Heijde, M Dougados*

**MORE CONTENTS ►**



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

COPE

Member since 2008  
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 1445** Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?



*U Lindström, K Bengtsson, T Olofsson, D Di Giuseppe, B Glinborg, H Forsblad-d'Elia, L T H Jacobsson, J Askling*

## Systemic sclerosis

- 1453** Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis

*A M Gaydosik, T Tabib, R Domsic, D Khanna, R Lafyatis, P Fuschiotti*

## Myositis

- 1461** Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies



*W I Che, H Westerlind, I E Lundberg, K Hellgren, R Kuja-Halkola, M Holmqvist*

## Vasculitis

- 1467** Treatment failure in giant cell arteritis



*S H Unizony, M Bao, J Han, Y Luder, A Pavlov, J H Stone*

- 1475** Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis

*C Ponte, S Monti, C A Scirè, P Delvino, N Khmelinskii, A Milanese, V Teixeira, F Brandolino, F Saraiva, C Montecucco, J E Fonseca, W A Schmidt, R A Luqmani*

## Crystal arthropathies

- 1483** Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan



*R Koto, A Nakajima, H Horiuchi, H Yamanaka*

## Letters

- 1491** Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis

*S Takanashi, Y Kaneko, T Takeuchi*

- 1493** Joint tenderness and ultrasound inflammation in DMARD-naïve patients with early rheumatoid arthritis

*N Paulshus Sundlisater, A-B Aga, I C Olsen, H B Hammer, T Uhlig, D van der Heijde, T K Kvien, E A Haavardsholm, S Lillegraven*

- 1494** Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis



*M Akbar, L MacDonald, L A N Crowe, K Carlberg, M Kurowska-Stolarska, P L Ståhl, S J B Snelling, I B McInnes, N L Millar*

- 1497** Effects of face masks on oxygen saturation and functional measures in patients with connective tissue disorder-associated interstitial lung disease

*A Vijayan, S Ahmed, S Joseph, A Sukumaran, S Ahmed, P Shenoy*

- 1498** Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group

*F Ursini, P Ruscitti, S D'Angelo, F Cacciapaglia, R De Angelis, C Campochiaro, F Caso, M De Santis, I Di Cola, S Parisi, V Raimondo, G Abignano, L Costa, J Ciaffi, L Dagna, A Iagnocco, F Iannone, R Meliconi, R Giacomelli, C Ferri*

- 1501** Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan

*Y Kirino, K Takase-Minegishi, N Tsuchida, L Hirahara, Y Kunishita, R Yoshimi, H Nakajima*

## Electronic pages

- e172** Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka *et al*

*L C Berkhout, M J l'Ami, G J Wolbink, T Rispens*

- e173** Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka *et al*' by Berkhout *et al*

*Y Tanaka, K Oba, T Takeuchi*

- e174** Gut-derived CD8<sup>+</sup> tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients

*G Guggino, A Rizzo, D Mauro, F Macaluso, F Ciccia*

- e175** Response to: 'Gut-derived CD8<sup>+</sup> tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients' by Guggino *et al*

*Z Qaiyum, E Gracey, YC Yao, R D Inman*

- e176** Gut microbiome in rheumatic diseases

*S Moiseev, V Rameev, E Karovaikina, L Lysenko (Kozlovskaya)*

- e177** The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus  
*S-X Zhang, J Wang, J-W Chen, M-X Zhang, Y-F Zhang, F-Y Hu, Z-Q Lv, C Gao, Y-F Li, X-F Li*
- e178** Response to: 'The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus' by Zhang *et al* and the phylogeny of a candidate pathobiont in lupus nephritis  
*G J Silverman, D F Azzouz*
- e179** Bone health in patients with systemic lupus erythematosus  
*S-W Lai, Y-H Kuo, K-F Liao*
- e180** Association between osteoporosis and statins therapy  
*S-W Lai*
- e181** Response to: 'Association between osteoporosis and statins therapy' by Lai  
*M Leutner, C Matzhold, L Bellach, C Deischinger, J Harreiter, S Thurner, P Klimek, A Kautzky-Willer*
- e182** Anti-Ku antibodies: important points to consider  
*M Mahler, M Satoh, M J Fritzler*
- e183** Response to: 'Anti-Ku antibodies: important points to consider' by Mahler *et al*  
*M Ogawa-Momohara, Y Muro, M Akiyama*
- e184** Temporal ultrasound for monitoring tocilizumab treatment in giant cell arteritis: seeing beyond serum markers?  
*G Evangelatos, G E Fragoulis, A Iliopoulos*
- e185** Involvement of industry in review articles published in Annals of the Rheumatic Diseases  
*M Rudwaleit*
- e186** Correction: *Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double blind, placebo-controlled, dose-ranging study*
- e187** Correction: *Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis*